HOOKIPA PHARMA INC. news, videos and press releases
For more news please use our advanced search feature.
HOOKIPA PHARMA INC. - More news...
HOOKIPA PHARMA INC. - More news...
- HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab
- HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated Cancers
- HOOKIPA Pharma Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
- HOOKIPA Pharma to Host Investor Call on HB-200 and Planned Path to Registration
- HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
- HOOKIPA Pharma to Participate in Leerink Partners Global Biopharma Conference
- HOOKIPA Pharma Provides Update on Business Priorities and Oncology Partnership Programs
- HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development Organization
- HOOKIPA Pharma Announces $21.25 Million Equity Investment from Gilead Sciences
- HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-500 for the Treatment of Human Immunodeficiency Virus
- HOOKIPA Pharma Reports Third Quarter 2023 Financial Results and Recent Business Highlights
- HOOKIPA Pharma Presents Positive Biomarker and Translational Data on HB-200 Monotherapy at Society for Immunotherapy of Cancer 2023
- HOOKIPA Pharma to Report Third Quarter 2023 Financial Results and Recent Business Highlights on November 9, 2023
- HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023
- HOOKIPA Pharma announces publication of preclinical data of hepatitis B virus (HBV) therapeutic vaccine developed in collaboration with Gilead Sciences
- HOOKIPA Announces Executive Leadership Change
- HOOKIPA Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
- HOOKIPA Pharma to participate in upcoming investor conferences in September
- HOOKIPA Pharma Reports Second Quarter 2023 Financial Results and Recent Business Highlights
- HOOKIPA Pharma to Report Second Quarter 2023 Financial Results and Recent Business Highlights on August 10, 2023
- HOOKIPA Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
- HOOKIPA Pharma Announces Pricing of $50.0 Million Public Offering of Common Stock and Non-Voting Convertible Preferred Stock
- HOOKIPA Pharma Announces Positive Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab in Patients with HPV16+ Head and Neck Cancers
- HOOKIPA Pharma Reports First Quarter 2023 Financial Results and Recent Business Highlights
- HOOKIPA Announces First Person Dosed in Phase 1a/b Clinical Trial of HB-400, in Collaboration with Gilead, for Treatment of Hepatitis B
- HOOKIPA Pharma to Participate in Upcoming Investor Conferences in May
- HOOKIPA Pharma to Report First Quarter 2023 Financial Results and Recent Business Highlights on May 11, 2023
- HOOKIPA to Present a Trial in Progress Poster on its Prostate Cancer Phase 1/2 Clinical Trial at ASCO
- HOOKIPA Pharma to Participate in the Van Lanschot Kempen Life Sciences Conference
- HOOKIPA Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)